ITCI Jan 2025 100.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:10PM EDT. Market open.
| Previous Close | 2.4000 |
| Open | 2.4000 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 100.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 2.4000 - 2.4000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 68 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Investor's Business DailyIntra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
The Relative Strength (RS) Rating for Intra-Cellular Therapies stock entered a new percentile Thursday, with a rise from 75 to 87. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against the rest of the market.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
© 2024 Yahoo. All rights reserved.